Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

OBJECTIVES: Immune checkpoint inhibitors (ICIs) targeting the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) pathways have demonstrated survival improvements in multiple advanced cancers, but also cause immune-related adverse events (IRAEs). IRAEs wit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Cappelli, Laura C, Gutierrez, Anna Kristina, Baer, Alan N, Albayda, Jemima, Manno, Rebecca L, Haque, Uzma, Lipson, Evan J, Bleich, Karen B, Shah, Ami A, Naidoo, Jarushka, Brahmer, Julie R, Le, Dung, Bingham, Clifton O
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5333990/
https://ncbi.nlm.nih.gov/pubmed/27307501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2016-209595
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados